OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer and Metastasis Reviews is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners	100
Glioma: molecular signature and crossroads with tumor microenvironment	90
Checkpoint inhibitor therapy for metastatic triple-negative breast cancer	71
Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer	70
Secreted frizzled-related protein 2: a key player in noncanonical Wnt signaling and tumor angiogenesis	61
The adipocyte microenvironment and cancer	60
Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers	54
Targeting KRAS in pancreatic cancer: new drugs on the horizon	52
Neuroblastoma and the epigenome	51
The obesity-breast cancer link: a multidisciplinary perspective	51
Lipid metabolism reprogramming in renal cell carcinoma	49
The comprehensive landscape of miR-34a in cancer research	45
Gastrointestinal stromal tumor: a review of current and emerging therapies	43
The plasticity of pancreatic cancer stem cells: implications in therapeutic resistance	41
Anti-HER2 therapy in metastatic breast cancer: many choices and future directions	40
The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions	39
An overview of genetic mutations and epigenetic signatures in the course of pancreatic cancer progression	37
Targeting the cytoskeleton against metastatic dissemination	36
Neutrophil-derived granule cargoes: paving the way for tumor growth and progression	36
Inflammatory bowel disease and carcinogenesis	35
Rethinking the biology of metastatic melanoma: a holistic approach	33
Role of non-coding RNAs in tumor progression and metastasis in pancreatic cancer	32
Chemokines orchestrate tumor cells and the microenvironment to achieve metastatic heterogeneity	31
The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options	30
The role of microbiome in pancreatic cancer	30

Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma—backbone or add-on in immune-oncology?	28
Obesity: a perfect storm for carcinogenesis	27
Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis	27
Nanoparticle-mediated cancer cell therapy: basic science to clinical applications	27